29 January 2025 in Blood Advances
Acute promyelocytic leukemia (APL), distinguished by the presence of PML::RARA fusion transcript, is a medical emergency because of its high early death rate, which is preventable when diagnosed early. Current diagnostic methods are precise and reliable but are time intensive, require sophisticated instruments, and analytical expertise. This study has redefined APL identification by CRISPR system (RAPID-CRISPR) to rapidly (<3 hours) detect PML::RARA. APL cell lines (NB4 and UF-1) and bone marrow/peripheral blood samples from 74 patients with APL (66/8, retrospective/prospective) and 48 controls were included in the study. We used a DETECTR (DNA endonuclease-targeted CRISPR transreporter) assay to identify the bcr1, bcr2, and bcr3 PML::RARA isoforms. To ensure high specificity, we used PML::RARA–specific loop-mediated isothermal amplification (LAMP) primers, synthetic protospacer-adjacent motif sites, and isoform-specific CRISPR RNAs. RAPID-CRISPR recognized APL with 100% sensitivity and 100% specificity in an ambispective cohort of patient samples. Furthermore, our blinded validation approach to detect PML::RARA in an unbiased manner provides an additional layer in the diagnostic precision of APL. RAPID-CRISPR demonstrated superior sensitivity, detecting as few as 1 copy of PML::RARA compared with 10 copies by the gold-standard reverse transcriptase qualitative and quantitative polymerase chain reaction. The nucleic acid extraction–free protocol combined with the 1-step reverse transcriptase LAMP–based DETECTR followed by lateral flow readout makes the RAPID-CRISPR assay suitable for diagnosing APL in point-of-care settings. This simple, cost-effective tool, with its easy-to-read format, is particularly valuable in underresourced regions. The assay facilitates timely diagnosis and prompt administration of lifesaving therapies such as all-trans retinoic acid and arsenic trioxide in APL.
12 February 2026 in Molecular Carcinogenesis
Early diagnosis of acute promyelocytic leukemia (APL), driven by PML‐RARA oncoprotein, is vital for survival, as delays can cause fatal coagulopathy without prompt therapeutic intervention of all‐trans retinoic acid and arsenic trioxide. Although APL is diagnosed using microscopy, immunophenotyping, and FISH/PCR for PML‐RARA, morphological overlap with acute myeloid leukemia (AML) ‐M5 and AML‐M2 complicates identification. In resource‐limited settings, unavailability of real time ‐quantitiative PCR (RQ‐PCR) or delays in FISH/qualitative RT‐PCR results increase the risk of missed or late diagnosis with fatal outcomes. Podoplanin (PDPN), a glycoprotein overexpressed in APL cells, interacts with platelets to mediate thrombosis. We evaluated PDPN expression, regulation, and diagnostic potential in APL. PDPN mRNA (RQ‐PCR) and surface protein (flow cytometry) were significantly higher in APL than non‐APL AML ( p < 0.0001), consistent with TCGA‐LAML and BEATAML1.0 datasets. Sensitivity and specificity were 80.7% and 71.43% by RQ‐PCR, and 92.86% and 100% by flow cytometry, respectively. Chromatin immunoprecipitation followed by quantitative PCR (ChIP‐qPCR) and TGF‐ β1 stimulation confirmed SMAD binding and PDPN upregulation. Pharmacological inhibition of TGF‐β1 ligand using luspatercept reduced SMAD phosphorylation and PDPN expression, indicating TGF‐β/SMAD transcriptionally regulates PDPN. Additionally, ELISA‐based serum profiling showed significantly elevated TGF‐β1 levels in APL patients compared to non‐APL AML ( p < 0.0001). These findings identify PDPN overexpression as a downstream consequence of TGF‐β/SMAD signaling and highlight its potential as a diagnostic biomarker for APL.